Form 8-K - Current report:
SEC Accession No. 0001193125-24-216321
Filing Date
2024-09-10
Accepted
2024-09-10 07:11:01
Documents
16
Period of Report
2024-09-10
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d885072d8k.htm   iXBRL 8-K 44922
2 EX-99.1 d885072dex991.htm EX-99.1 33299
6 GRAPHIC g885072g0910083316807.jpg GRAPHIC 2721
7 GRAPHIC g885072g0910083738871.jpg GRAPHIC 2267
  Complete submission text file 0001193125-24-216321.txt   225673

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20240910.xsd EX-101.SCH 2515
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20240910_lab.xml EX-101.LAB 17957
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20240910_pre.xml EX-101.PRE 11241
19 EXTRACTED XBRL INSTANCE DOCUMENT d885072d8k_htm.xml XML 3761
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 241288741
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)